Supplememtary Methods, Figures 1 - 4, Tables 1 - 3 from ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy

Supplementary Material and Methods : Plasma pharmacokinetics of topotecan with and without the ABCG2 inhibitor Ko143. Supplementary Figure S1: RNA expression of ABC transporters in human and mouse Group3 medulloblastoma. Supplementary Figure S2: Abcg2 protein expression in mouse bone marrow from Abcg2-null mice and Group3 medulloblastoma tumor cells. Supplementary Figure S3: Dose-response of chemotherapeutic agents alone or with two Abcg2 inhibitors, Ko143 or Tariquidar. Supplementary Figure S4: Weight measurement and Abcg2 protein expression in mouse Group3 medulloblastoma during treatment. Supplementary Table 1: Affymetrix gene array analysis of genes in the porphyrin pathway in granule neuron progenitors (GNPs) and Mouse Group3 medulloblastoma tumor cells. Supplementary Table 2: Chemotherapeutic drugs tested on mouse Group3 medulloblastoma tumor cells. Supplementary Table 3: Plasma PK paramaters of topotecan after administration as single agent or in combination with the Abcg2 inhibitor Ko143.